Coherus Oncology, Inc.
CHRS
$1.20
$0.065.26%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 16.22% | -3.44% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 16.22% | -3.44% | |||
| Cost of Revenue | 11.09% | -5.71% | |||
| Gross Profit | 18.53% | -2.38% | |||
| SG&A Expenses | -9.31% | 9.97% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -3.76% | -13.51% | |||
| Operating Income | 10.57% | 16.47% | |||
| Income Before Tax | 9.71% | 20.31% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 9.71% | 20.31% | |||
| Earnings from Discontinued Operations | 1,013.51% | -115.99% | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 46.17% | -1.82% | |||
| EBIT | 10.57% | 16.47% | |||
| EBITDA | 10.78% | 16.78% | |||
| EPS Basic | 52.56% | 10.14% | |||
| Normalized Basic EPS | 20.45% | 25.50% | |||
| EPS Diluted | 52.56% | 10.14% | |||
| Normalized Diluted EPS | 20.45% | 25.50% | |||
| Average Basic Shares Outstanding | 13.50% | 13.32% | |||
| Average Diluted Shares Outstanding | 13.50% | 13.32% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||